147 related articles for article (PubMed ID: 17551309)
1. Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.
Verma S; Wong NS; Trudeau M; Joy A; Mackey J; Dranitsaris G; Clemons M
Am J Clin Oncol; 2007 Jun; 30(3):297-302. PubMed ID: 17551309
[TBL] [Abstract][Full Text] [Related]
2. Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer.
Liu XH; Man YN; Cao R; Liu C; Wu XZ
Curr Med Res Opin; 2014 Jun; 30(6):1017-24. PubMed ID: 24528110
[TBL] [Abstract][Full Text] [Related]
3. Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer.
Lin PC; Wang WS; Yang MH; Yen CC; Chao TC; Hsiao LT; Chen PM
J Chin Med Assoc; 2006 Jul; 69(7):304-9. PubMed ID: 16903643
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer.
Stuart NS; McIllmurray MB; Bishop JL; Johnston SR; Price CG; O'Reilly SM; Joffe JK; Neave F; Whipp EC
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):152-6. PubMed ID: 18083354
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.
Pajk B; Cufer T; Canney P; Ellis P; Cameron D; Blot E; Vermorken J; Coleman R; Marreaud S; Bogaerts J; Basaran G; Piccart M
Breast; 2008 Apr; 17(2):180-5. PubMed ID: 17976988
[TBL] [Abstract][Full Text] [Related]
7. Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Zhang J; Gu SY; Gan Y; Wang ZH; Wang BY; Guo HY; Wang JL; Wang LP; Zhao XM; Hu XC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):103-13. PubMed ID: 23053266
[TBL] [Abstract][Full Text] [Related]
8. Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
Palomo AG; Glogowska I; Sommer H; Malamos N; Kilar E; Vega JM; Torrecillas L; Delozier T; Ettl J; Finek J
Anticancer Res; 2012 Oct; 32(10):4539-45. PubMed ID: 23060583
[TBL] [Abstract][Full Text] [Related]
9. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Pallis AG; Boukovinas I; Ardavanis A; Varthalitis I; Malamos N; Georgoulias V; Mavroudis D
Ann Oncol; 2012 May; 23(5):1164-1169. PubMed ID: 21937705
[TBL] [Abstract][Full Text] [Related]
10. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Verma S; Ilersich AL
Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
13. A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Orphanos G; Alexopoulos A; Malliou S; Ioannidis G; Ardavanis A; Kandylis C; Stavrakakis J; Rigatos G
J Cancer Res Clin Oncol; 2010 Jan; 136(1):115-21. PubMed ID: 19672628
[TBL] [Abstract][Full Text] [Related]
14. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines.
Campone M; Dobrovolskaya N; Tjulandin S; Chen SC; Fourie S; Mefti F; Konstantinova M; Lefresne F; Meheust N; Jassem J
Breast J; 2013; 19(3):240-9. PubMed ID: 23528159
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer.
Di Seri M; De Sanctis R; Quadrini S; Adua D; Stumbo L; Del Signore E; Gori B; Grassi P; Basile ML; Longo F
J Chemother; 2011 Apr; 23(2):110-3. PubMed ID: 21571629
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
Kellokumpu-Lehtinen PL; Sunela K; Lehtinen I; Joensuu H; Sjöström-Mattson J;
Clin Breast Cancer; 2006 Dec; 7(5):401-5. PubMed ID: 17239265
[TBL] [Abstract][Full Text] [Related]
18. Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.
Castaneda CA; Gómez HL
Clin Breast Cancer; 2009 Nov; 9(4):E1-3. PubMed ID: 19933071
[TBL] [Abstract][Full Text] [Related]
19. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K
Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.
Ahn JH; Kim SB; Kim TW; Ahn SH; Kim SM; Park JM; Lee JS; Kang YK; Kim WK
J Korean Med Sci; 2004 Aug; 19(4):547-53. PubMed ID: 15308846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
